Abstract
Stroke is a serious neurological disease and the third leading cause of death in the western world. In roughly 15 % of the cases, the cause is due to an intracranial haemorrhage, and the remaining 85 % represent ischemic strokes. Ischemic stroke is caused by the occlusion of a cerebral artery either by an embolus or by local thrombosis. Several studies have shown an involvement of the endothelin system in ischemic stroke. This review aims to examine the alterations of vascular endothelin receptor expression in ischemic stroke. Furthermore, studies of the intracellular signalling pathways leading to the enhanced expression of vascular endothelin receptors show that both protein kinase C (PKC) and mitogen activating protein kinase (MAPK) play important roles. The results from this work provide new perspectives on the pathophysiology of ischemic stroke, and give a possible explanation to the beneficial effects of treatment with PKC and MAPK inhibitors to limit the infarct volume.
Keywords: Cerebrovascular Endothelin Receptor, Cerebral Ischemia, neurological disease, Ischemic stroke, intracranial haemorrhage, protein kinase C (PKC), MAPK inhibitors
Current Vascular Pharmacology
Title: Cerebrovascular Endothelin Receptor Upregulation in Cerebral Ischemia
Volume: 7 Issue: 1
Author(s): Lars Edvinsson
Affiliation:
Keywords: Cerebrovascular Endothelin Receptor, Cerebral Ischemia, neurological disease, Ischemic stroke, intracranial haemorrhage, protein kinase C (PKC), MAPK inhibitors
Abstract: Stroke is a serious neurological disease and the third leading cause of death in the western world. In roughly 15 % of the cases, the cause is due to an intracranial haemorrhage, and the remaining 85 % represent ischemic strokes. Ischemic stroke is caused by the occlusion of a cerebral artery either by an embolus or by local thrombosis. Several studies have shown an involvement of the endothelin system in ischemic stroke. This review aims to examine the alterations of vascular endothelin receptor expression in ischemic stroke. Furthermore, studies of the intracellular signalling pathways leading to the enhanced expression of vascular endothelin receptors show that both protein kinase C (PKC) and mitogen activating protein kinase (MAPK) play important roles. The results from this work provide new perspectives on the pathophysiology of ischemic stroke, and give a possible explanation to the beneficial effects of treatment with PKC and MAPK inhibitors to limit the infarct volume.
Export Options
About this article
Cite this article as:
Edvinsson Lars, Cerebrovascular Endothelin Receptor Upregulation in Cerebral Ischemia, Current Vascular Pharmacology 2009; 7 (1) . https://dx.doi.org/10.2174/157016109787354178
DOI https://dx.doi.org/10.2174/157016109787354178 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Approaches to Target Profiling of Natural Products
Current Medicinal Chemistry Importance of Dietary Supplements to the Health
Current Nutrition & Food Science Hypertension in China: Past, Present, and Future
Current Hypertension Reviews Antihypertensive Therapy: Role of Aldosterone Antagonists
Current Pharmaceutical Design A Direct Interaction Between Mitochondrial Proteins and Amyloid-β Peptide and its Significance for the Progression and Treatment of Alzheimer’s Disease
Current Medicinal Chemistry Beyond the HapMap Genotypic Data: Prospects of Deep Resequencing Projects
Current Bioinformatics Determining Effective Diabetic Care; A Multicentre - Longitudinal Interventional Study
Current Pharmaceutical Design Overview of Dietary Influences on Atherosclerotic Vascular Disease:Epidemiology and Prevention
Cardiovascular & Hematological Disorders-Drug Targets The Role of the Chemokines in Myocardial Ischemia and Reperfusion
Current Vascular Pharmacology Directions for Enhancement of the Therapeutic Efficacy of Mesenchymal Stem Cells in Different Neurodegenerative and Cardiovascular Diseases: Current Status and Future Perspectives
Current Stem Cell Research & Therapy Tetrahydrobioterin (BH4) Pathway: From Metabolism to Neuropsychiatry
Current Neuropharmacology Effects of CYP2C19 Polymorphism on Endothelial Function, Arterial Stiffness and Inflammation in Coronary Artery Disease Patients Under Clopidogrel Treatment
Current Pharmaceutical Design Beta-Blockers for the Treatment of Essential Hypertension: What are the Arguments Against Their Use as First Line Therapy?
Current Hypertension Reviews Genistein: A Phytoestrogen with Multifaceted Therapeutic Properties
Mini-Reviews in Medicinal Chemistry PGD and Prenatal Diagnosis: Comparison and Review in Different Genetic Disorders
Current Women`s Health Reviews Primary and Secondary Hypertriglyceridaemia
Current Drug Targets Nanotechnology for Delivery of Drugs and Biomedical Applications
Current Clinical Pharmacology Analgesic Considerations for Liver Transplantation Patients
Current Clinical Pharmacology Recent Advances in the Synthesis of Biologically Active Cinnoline, Phthalazine and Quinoxaline Derivatives
Current Organic Chemistry Uric Acid and Diabetes: Is there a Link?
Current Pharmaceutical Design